DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* GENOWAY *


 

1999 - Rhône-Alpes
Lyon
www.genoway.com

 

Contract, Research
Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests
Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats)
Clients: Research labs
info@genoway.com

Age: 18 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA (HEC)]
Sc.Dir.-CSO:
Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome]
BusDev: Thiam (Kader)
Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public

Turnover (M€) : 6.6 (2009), 6.7 (2008), 3.5 (2006)
Total funding (M€) : 10.8
Last funding (M€) : 1.1
Focus : Genome
Position : Subcontractor
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .04 Partnering distribution agreement for Internal Ribosome Entry Site (IRES) technology by StemCells to Genoway (exclusive worldwide licence) MKTG [13 years]
2012 .03 Partnering distribution agreement for all services of animal model creation and phenotpying by Phenopro (ex-ICS) to Genoway (exclusive worldwide licence) MKTG [13 years]
2011 .07 Licensing-in of RMCE technology from Bluebird Bio (USA) for genetically modified rodents LICIN [12 years]
2010 .06 Partnering sales agreement with 3 major Japanese biopharmaceutical companies, as new customers MKTG [11 years]
2010 .05 Partnering research agreement with Griffith University (Australia) for olfactory stem cells technology R&D [11 years]
2009 .10 Licensing-in of Flex technology, developed by Prof. Pierre Chambon and Dr Norbert Ghyselinck at the IGBMC (Strasbourg) LICIN [10 years]
2009 .02 Launch of StemCellHY, a new production technology including ThromboGenics' proprietary stem cell lines MKTG [9 years]
2008 .06 Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genfit, SpiBio, Roowin and Academic Institutions, over 5 years DEBT [9 years]
2007 .00 Partnering research agreement with Boehringer Ingelheim (USA) to provide murine models R&D [7 years]
2007 .05 Seed financing : 1.1 M€, by NGFN (National Genome Research Network) in Germany SFIN [8 years]
2007 .05 Listing on Alternext : 6.2 M€ (23% of shares) PBO [8 years]
2006 .05 Partnering distribution agreement with Charles River (USA market, co-promotion) MKTG [7 years]
2005 .00 Acquisition of Murinus (Germany) ACQ+ [5 years]
2004 .09 2nd round-financing : 4.0 M€, led by CDC Entreprises, Siparex Ventures RFINB [5 years]
2003 .04 1st round-financing : 3.5 M€, led by Dassault Developpement, with Qualis, Rhône Alpes Création RFINA [4 years]
1999 .03 Company founded by Alexandre Fraichard and Gilles de Poncins, as a spin-off from Normale Sup (Lyon) ORGF [0 year]

Actualisation / Updating: 5-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende